within Pharmacolibrary.Drugs.ATC.V;

model V03AB31
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 3000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AB31</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Prussian blue is an insoluble ferric hexacyanoferrate(II) compound used as an antidote for certain kinds of heavy metal poisoning, most notably thallium and radioactive cesium. It binds to these metals in the gastrointestinal tract to prevent their absorption and facilitate their elimination in feces. Prussian blue is an FDA-approved orphan drug.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies are available; estimates are based on clinical use and drug properties. Prussian blue is not absorbed systemically and acts locally in the gut. Parameters are estimated as per oral administration in adults.</p><h4>References</h4><ol><li><p>Sandal, N, et al., &amp; Yadav, M (2023). Oral formulation of Prussian blue with improved efficacy for prophylactic use against thallium. <i>Drug development and industrial pharmacy</i> 49(2) 149–158. DOI:<a href=\"https://doi.org/10.1080/03639045.2023.2189958\">10.1080/03639045.2023.2189958</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36912805/\">https://pubmed.ncbi.nlm.nih.gov/36912805</a></p></li><li><p>Rauws, AG (1974). Thallium pharmacokinetics and its modification by Prussian Blue. <i>Naunyn-Schmiedeberg&#x27;s archives of pharmacology</i> 284(3) 294–306. DOI:<a href=\"https://doi.org/10.1007/BF00500348\">10.1007/BF00500348</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4279354/\">https://pubmed.ncbi.nlm.nih.gov/4279354</a></p></li><li><p>Hu, S, et al., &amp; Cai, X (2022). A pH-Driven indomethacin-loaded nanomedicine for effective rheumatoid arthritis therapy by combining with photothermal therapy. <i>Journal of drug targeting</i> 30(7) 737–752. DOI:<a href=\"https://doi.org/10.1080/1061186X.2022.2053539\">10.1080/1061186X.2022.2053539</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35282742/\">https://pubmed.ncbi.nlm.nih.gov/35282742</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AB31;
